CAR T-cell therapy has shown some remarkable success, including several market approvals. However, challenges remain such as antigen escape, tumor heterogeneity, and solid tumors.

Dual CAR T-cell therapy has emerged as an innovative strategy that has the potential to overcome these limitations and help cell therapy developers bring new cell therapies to market.

In this white paper, you will learn about:

• The evolution of CAR design
• The potential clinical advantages of dual CAR constructs
• Manufacturing challenges associated with their clinical translation
• How to optimize manufacturing processes with Revvity’s LentiBOOST™ transduction enhancer and BioLegend’s Cell-Vive™ reagents

Why cell therapy leaders need this resource:

• Understand how dual targeting reduces antigen escape and improves treatment durability
• Identify critical factors for successful dual CAR manufacturing
• Get recommendations of proven optimization strategies

LentiBOOST Pharma-Grade: For research use only. Not for use in diagnostic procedures.

LentiBOOST GMP Grade: Not for diagnostic use. Other applications must be authorized by a license from Revvity.

Cell-Vive™ GMP: For research use only. Not for use in diagnostic procedures.